WO2013033092A3 - Streptococcus suis pilus antigens - Google Patents

Streptococcus suis pilus antigens Download PDF

Info

Publication number
WO2013033092A3
WO2013033092A3 PCT/US2012/052656 US2012052656W WO2013033092A3 WO 2013033092 A3 WO2013033092 A3 WO 2013033092A3 US 2012052656 W US2012052656 W US 2012052656W WO 2013033092 A3 WO2013033092 A3 WO 2013033092A3
Authority
WO
WIPO (PCT)
Prior art keywords
streptococcus suis
pilus antigens
compositions
suis
pilus
Prior art date
Application number
PCT/US2012/052656
Other languages
French (fr)
Other versions
WO2013033092A2 (en
Inventor
Axel Neubauer
Hilda Elizabeth Smith
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of WO2013033092A2 publication Critical patent/WO2013033092A2/en
Publication of WO2013033092A3 publication Critical patent/WO2013033092A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to compositions and their use for stimulating an immune response to Streptococcus suis in animals, preferably swine, or humans. Preferred compositions of the invention are able to illicit immune responses to two or more serotypes of S. suis. Methods of making and using compositions of the invention are provided.
PCT/US2012/052656 2011-09-03 2012-08-28 Streptococcus suis pilus antigens WO2013033092A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530969P 2011-09-03 2011-09-03
US61/530,969 2011-09-03

Publications (2)

Publication Number Publication Date
WO2013033092A2 WO2013033092A2 (en) 2013-03-07
WO2013033092A3 true WO2013033092A3 (en) 2013-07-18

Family

ID=46826920

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/052656 WO2013033092A2 (en) 2011-09-03 2012-08-28 Streptococcus suis pilus antigens

Country Status (1)

Country Link
WO (1) WO2013033092A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113151516B (en) * 2021-04-01 2023-11-28 武汉轻工大学 Human high-risk zoonotic streptococcus suis specific sequence, detection primer and application
CN117794565A (en) * 2021-08-03 2024-03-29 英特维特国际股份有限公司 Vaccine for protection against multiple serotypes of streptococcus suis
CN117794564A (en) * 2021-08-03 2024-03-29 英特维特国际股份有限公司 Vaccine for protection against multiple serotypes of streptococcus suis
EP4380612A1 (en) * 2021-08-03 2024-06-12 Intervet International B.V. A vaccine for protection against streptococcus suis of various serotypes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010079464A1 (en) * 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
WO2011009771A2 (en) * 2009-07-20 2011-01-27 Universidad de Córdoba Immunogenic and therapeutic compositions for streptococcus suis

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US382425A (en) 1888-05-08 Brandt
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1990001543A1 (en) 1988-07-29 1990-02-22 Intracel Corporation Method for the genetic expression of heterologous proteins by cells transfected in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
DE69032284T2 (en) 1989-03-21 1998-10-08 Vical Inc EXPRESSION OF EXOGENOUS POLYNUCLEOTIDE SEQUENCES IN VERTEBLE
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
FR2711670B1 (en) 1993-10-22 1996-01-12 Pasteur Institut Nucleotide vector, composition containing it and vaccine for immunization against hepatitis.
ES2348013T3 (en) 1994-01-27 2010-11-26 University Of Massachusetts Medical Center IMMUNIZATION BY INOCULATION OF A DNA TRANSCRIPTION UNIT.
EP0758397B1 (en) 1994-04-29 2005-06-22 Baxter Healthcare S.A. Recombinant poxviruses with foreign polynucleotides in essential regions
JPH11502222A (en) 1995-03-23 1999-02-23 キャンタブ ファーマシューティカルズ リサーチ リミティド Gene supply vector
JP2002512501A (en) 1996-07-03 2002-04-23 メリアル インコーポレイテッド Recombinant canine adenovirus (CAV) containing exogenous DNA
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010079464A1 (en) * 2009-01-12 2010-07-15 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
WO2011009771A2 (en) * 2009-07-20 2011-01-27 Universidad de Córdoba Immunogenic and therapeutic compositions for streptococcus suis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAISUKE TAKAMATSU ET AL: "Genetic organization and preferential distribution of putative pilus gene clusters in Streptococcus suis", VETERINARY MICROBIOLOGY, vol. 138, no. 1-2, 1 July 2009 (2009-07-01), pages 132 - 139, XP055048090, ISSN: 0378-1135, DOI: 10.1016/j.vetmic.2009.02.013 *
GARIBALDI M ET AL: "Immunoprotective activities of a Streptococcus suis pilus subunit in murine models of infection", VACCINE, ELSEVIER LTD, GB, vol. 28, no. 20, 30 April 2010 (2010-04-30), pages 3609 - 3616, XP027000087, ISSN: 0264-410X, [retrieved on 20100114] *
LINA LIU ET AL: "Identification and Experimental Verification of Protective Antigens Against Streptococcus suis Serotype 2 Based on Genome Sequence Analysis", CURRENT MICROBIOLOGY, SPRINGER-VERLAG, NE, vol. 58, no. 1, 7 October 2008 (2008-10-07), pages 11 - 17, XP019655171, ISSN: 1432-0991 *
NAHUEL FITTIPALDI ET AL: "Mutations in the Gene Encoding the Ancillary Pilin Subunit of the Streptococcus suis srtF Cluster Result in Pili Formed by the Major Subunit Only", PLOS ONE, vol. 5, no. 1, 1 January 2010 (2010-01-01), pages e8426 - e8426, XP055048085, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0008426 *

Also Published As

Publication number Publication date
WO2013033092A2 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
HRP20181343T1 (en) Methods and compositions for inducing an immune response to egfrviii
EA201300585A1 (en) Immunomodulatory Oligonucleotides
EA201391597A1 (en) TOLEROGENIC SYNTHETIC NANO-MEDIA DECREASING IMMUNE RESPONSE TO THERAPEUTIC PROTEINS
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
WO2016094837A3 (en) Anti-c10orf54 antibodies and uses thereof
EP3426061A4 (en) Methods and compositions to improve weight loss and cardiometabolic health beyond diet and exercise
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
PH12014502855A1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
WO2014189973A3 (en) Anti-transferrin receptor antibodies and methods of use
WO2011113019A3 (en) Ctla4 proteins and their uses
PH12015502216A1 (en) Compositions and methods for improving the health of aquatic animals
CA2883095C (en) Antibody and protein formulations
WO2013177419A3 (en) Lipid nanoparticle compositions and methods of making and methods of using the same
WO2016014434A3 (en) Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
MX352324B (en) Multivalent synthetic nanocarrier vaccines.
WO2013054199A3 (en) Cmv antigens and uses thereof
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
WO2012149412A3 (en) Anti-endoglin (cd105) antibodies, immunoconjugates, and uses thereof
MX2014012977A (en) Anti-cd22 antibodies.
EA201391183A1 (en) METHODS OF STRENGTHENING IMMUNOGENSPECIFIC IMMUNE RESPONSES WITH THE HELP OF VECTOR VECTIONS
WO2012109238A3 (en) Methods for increasing immune responses using agents that directly bind to and activate ire-1
MX2016006189A (en) Extract of algae for use as an immunomodulatory agent.
WO2012170097A3 (en) Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
WO2013033092A3 (en) Streptococcus suis pilus antigens
WO2015095240A3 (en) Biosynthesis of 1-undecence and related terminal olefins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12756609

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 12756609

Country of ref document: EP

Kind code of ref document: A2